Medicskin Holdings Limited Overview
Medicskin Holdings is a micro-cap, founder-controlled medical aesthetics and dermatology clinic operator. All of its revenue comes from Hong Kong. It runs two doctor-led "Medicskin" medical skincare centres in prime locations: a full floor at New World Tower in Central and a centre at Ocean Centre in Tsim Sha Tsui. These are supported by the complementary "facematter" treatment and skincare brand and a small anti-ageing and preventive-medicine offering.
FY2026 revenue was HK$47.9 million. Of this, 81.8% came from prepaid courses of non-invasive and minimally invasive treatments: injectables, energy-based devices, HIFU and thread lifts. The group's main differentiators are its physician-performed model, anchored by a founder-dermatologist with more than 30 years in medical aesthetics, and a loyal client base (most clients have used its services for over five years).
Its main constraints are scale and structure. It is about 1/20th the size of Perfect Medical and about 1/80th the size of EC Healthcare. It has a heavy fixed-cost base, thin equity of HK$5.2 million, and a persistent net current liability position caused by HK$23.2 million of customer prepayments. FY2026 marked a return to a small profit after three loss-making years.
Company's own description (latest annual report)
In AR26 the company describes itself as a medical skincare service provider in Hong Kong. Its "Medicskin"-branded centres are strategically located in New World Tower, Central (a core business hub) and Ocean Centre, Tsim Sha Tsui (a prime shopping district with harbour views). Medicskin specialises in medical skincare services provided by registered medical practitioners. The "facematter" brand offers medical aesthetic and lifestyle beauty treatments that complement Medicskin. Facematter skincare products are sold through the group's own online shop and a third-party shopping platform [AR26].
Clinical focus covers two areas [AR26]:
Medical dermatology: acne, pigmentation, rosacea, dermatitis, eczema and warts.
Aesthetic improvement: skin rejuvenation, facial sculpting, body contouring, acne scars and enlarged pores, removal of undesirable naevi (moles), and hair removal.
The company states that most clients are long-term clients who have patronised the group for more than five years [AR26].
Revenue model
Revenue is generated through three disclosed service lines, all within a single reportable operating segment [AR26]:
-
Medical consultation services: private consultations for examination and diagnosis of skin conditions, with recommendations of skincare products or treatments. Recognised over time as the service is provided. FY2026: HK$954k (2.0% of revenue).
-
Prescription and dispensing services: prescription and dispensing of pharmaceutical products, medication and skincare products, including retail skincare sales. Recognised at a point in time when goods are collected or delivered. FY2026: HK$7,778k (16.2%).
-
Treatment services: non-invasive and minimally invasive procedures. These typically involve injection of botulinum toxin type A and hyaluronic acid, cauterisation, thread lifting, and device-based treatments using laser, radio-frequency (RF), high-intensity focused ultrasound (HIFU) and high-intensity facial electrical stimulation (HIFES). FY2026: HK$39,139k (81.8%).
Prepaid package mechanics. Treatment services are mostly sold as prepaid treatment packages. Cash received is deferred as a contract liability and recognised as revenue when treatments are delivered (an output method). Unused portions ("breakage") are recognised when the likelihood of redemption becomes remote, or in full when the package's service period expires [AR26]. At 31 March 2026, contract liabilities were HK$23.2 million. That is about 48% of annual revenue, and management expects it to be recognised over 12–36 months [AR26].
Value chain position
Medicskin is a downstream, consumer-facing clinical service provider. It buys pharmaceuticals, injectables, skincare products, treatment consumables and capital equipment from suppliers. In FY2026 it bought from 76 Hong Kong suppliers, 3 US suppliers and 1 Korean supplier [AR26]. Pharmaceuticals come only from licensed Hong Kong drug distributors.
Supplier concentration is meaningful. The largest supplier accounted for 18.5% of purchases and the top five for 56.3% (FY2025: 18.2% and 61.0%) [AR26]. Treatment devices are selected by the group's doctors and must be approved by the US FDA or Korea's MFDS, be CE-marked, or be supported by independent medical journals and clinical data [AR26].
The group does not manufacture. Facematter products are described as developed by a team with more than 20 years in cosmeceuticals [WEB]. Whether manufacturing is outsourced, and to whom, is not publicly disclosed.
Customer types and end-markets
Customers: individual retail consumers, overwhelmingly in Hong Kong. Customer concentration is negligible: the top five customers were under 4.4% of revenue (FY2025: 3.4%), and no customer exceeded 10% [AR26].
End-markets: - Hong Kong medical aesthetics, the core market.
-
Medical dermatology, the clinical niche.
-
Professional skincare retail, through the facematter e-shop.
-
Anti-ageing and preventive medicine: personalised wellness plans, genetic testing, and anti-ageing medicine and supplements [WEB].
Geography: 100% of external revenue comes from Hong Kong [AR26].
Independent characterisation
Medicskin is effectively a two-clinic, owner-physician practice wrapped in a listed holding structure. The economic engine is three things working together:
-
the founder's clinical reputation;
-
a loyal, mature client base that buys prepaid treatment courses;
-
periodic refresh of the device and injectable menu (FY2026: Ultherapy PRIME®) to keep existing clients spending.
The model has attractive unit-level features:
-
about 81% gross margin after consumables and products;
-
customer prepayments that fund working capital;
-
negligible receivables.
It is, however, burdened by structurally high fixed costs:
-
staff costs were 47.6% of revenue in FY2026;
-
prime-location rent (right-of-use depreciation plus lease interest) was about 12.4% of revenue;
-
directors' emoluments alone were 18.2% of revenue.
The result is extreme operating leverage. A swing of roughly ±5% in revenue moves the group between profit and loss. The company has a stated ambition to expand in Hong Kong and Mainland China [AR26][WEB]. In practice it has done the opposite: it disposed of a dormant Guangzhou subsidiary in FY2026 and has kept the same two-centre footprint. Its listed status adds compliance costs (audit fee HK$420k, plus GEM governance overhead) that are large relative to its earnings.
Strategy
Stated corporate strategy (AR26 MD&A and website, paraphrased)
The group's stated business strategy has three pillars [AR26][WEB]:
-
Expand presence: strategically expand and strengthen its presence in Hong Kong and Mainland China.
-
Enhance offerings: continuously improve the quality and variety of services and products.
-
Maintain expertise: maintain and enhance professional expertise.
The overarching aim is to create value and maximise returns for shareholders while providing reliable, high-quality professional services. Recurring themes in the FY2026 Chairman's Statement and Outlook [AR26]:
Cost discipline and operational optimisation: to counter intense competition and high operating costs.
Technology leadership: adopting cutting-edge treatment technologies (example: Ultherapy PRIME®).
Marketing: investment in online and social-media marketing, supplemented by targeted promotions such as new-treatment launch campaigns.
Centre renovation: planned renovation of the medical skincare centre(s) to raise service quality.
Cautious optimism: expects global uncertainty and intense competition in medical aesthetics in 2026, but sees steady medium- to long-term demand growth as medical aesthetics becomes a mainstream health and beauty solution, with growing acceptance of non-surgical and minimally invasive treatments.
There has been no investor day; the company does not hold earnings calls or publish investor presentations.
Strategic initiatives (last 24 months)
| Initiative | Timing | Detail | Target / metric | Source |
|---|---|---|---|---|
| Lease renewals at lower rent | Feb 2025 (benefit realised FY2026) | Centres and office leases renewed; RoU depreciation down 26% | HK$1.9m annual saving in FY2026 | [AR26] |
| Cost-saving programme | FY2026 | Lower directors' emoluments and staff salaries | Staff costs down HK$1.1m (-4.6%) | [AR26] |
| Ultherapy PRIME® launch | FY2026 | Upgraded micro-focused ultrasound lifting with DeepSEE® imaging | Not quantified | [AR26] |
| Digital and social-media marketing push | FY2026 | Online and social-media promotion; new-treatment launch campaigns | Not quantified | [AR26] |
| Consolidation of preventive-medicine unit | 1 Oct 2024 | Buy-out of 49% minority in Rightway Honour for US$2 | Simplified ownership | [AR26] |
| Back-office relocation | Late 2024 | Move to Sheung Wan office with central air-conditioning | Electricity use down 14.1% in FY2026 | [AR26] |
| PRC rationalisation | FY2026 | Disposal of dormant Guangzhou subsidiary | Immaterial | [AR26] |
| Centre renovation | Planned (timing not disclosed); Central lease extended to 2030 to cover it | Upgrade of Central centre | Capex amount not disclosed; capital commitments HK$0.5m for PP&E at 31 Mar 2026 | [AR26][DT1006] |
| New share option scheme | Adopted 27 Sep 2024 | Up to 39,673,600 shares (10%); service-provider sublimit 7,934,720 (2%); about 8 years remaining | No grants yet | [AR26] |
| ESG targets (2026–2028) | Set against 2023 baseline | GHG intensity -1%, energy intensity -1%, non-hazardous waste intensity -3% (cumulative) | All already exceeded in FY2026 | [AR26] |
Medium-term financial targets and guidance
No quantitative medium-term financial targets, revenue guidance or margin targets are publicly disclosed. The only forward-looking financial signal is the qualitative "cautiously optimistic" outlook [AR26].
Products & Services
The group discloses its portfolio at the level of treatment modality and brand, not SKU. Pricing for treatments and packages is not publicly disclosed in filings. The table goes item by item at the most granular level disclosed.
Medicskin Medical Skincare Centres (core brand)
| Offering | Description / capabilities | Target customer | Launch / latest version | Pricing model | Source |
|---|---|---|---|---|---|
| Medical consultation | Private doctor consultation; examination and diagnosis of skin conditions; tailored product and treatment recommendations | Patients with skin disease; aesthetic clients at intake | Since 2000 | Per-visit fee (amount not disclosed) | [AR26] |
| Prescription & dispensing | Prescription and dispensing of medicines, pharmaceutical products and skincare products; labelling to statutory standards | Existing patients | Since 2000 | Per item (not disclosed) | [AR26] |
| Acne treatment | Medical and procedural management of acne | Teens and adults with acne | Ongoing | Course/package (not disclosed) | [AR26][WEB] |
| Pigmentation treatment | Laser/light-based and medical management of pigmentation | Adults with melasma, spots and similar | Ongoing | Course/package | [AR26] |
| Rosacea, dermatitis, eczema, warts | Medical dermatology treatments (including cauterisation for warts) | Patients with inflammatory or infective skin disease | Ongoing | Consultation plus prescription | [AR26] |
| Skin rejuvenation | Energy-based devices (laser, RF), injectables | Ageing-skin clients | Ongoing | Prepaid course | [AR26] |
| Facial sculpting / contouring | Botulinum toxin type A, hyaluronic acid dermal fillers, thread lifting, HIFU | Aesthetic clients | Ongoing | Prepaid course | [AR26][dividend.watch profile] |
| Body contouring | Device-based body contouring (specific devices not named in AR26) | Aesthetic clients | Ongoing | Prepaid course | [AR26] |
| Acne scars & enlarged pores | Laser and RF resurfacing | Post-acne clients | Ongoing | Prepaid course | [AR26] |
| Naevi (mole) removal | Removal of undesirable naevi (cauterisation/laser) | General | Ongoing | Per procedure | [AR26] |
| Hair removal | Laser/light-based hair removal | General | Ongoing | Prepaid course | [AR26] |
| Ultherapy PRIME® (flagship launch FY2026) | Upgraded Ultherapy®. Micro-focused ultrasound delivers energy to deep skin layers; enhanced DeepSEE® real-time imaging visualises skin layers so energy reaches the SMAS fascia; stimulates collagen and elastin for lifting and tightening. | Clients seeking non-surgical lifting | Introduced during FY2026 | Per session/package (not disclosed) | [AR26] |
| HIFES treatments | High-intensity facial electrical stimulation (muscle-toning facial treatments) | Aesthetic clients | Disclosed in AR26 | Prepaid course | [AR26] |
| RF and laser platforms | Radio-frequency and laser devices (brand names not disclosed); devices must be FDA/MFDS/CE-approved or clinically supported | Aesthetic and dermatology clients | Ongoing; equipment refreshed (FY2026 additions HK$1.69m medical equipment) | Prepaid course | [AR26] |
facematter (brand)
| Offering | Description | Target customer | Channel | Source |
|---|---|---|---|---|
| facematter medical-aesthetic and lifestyle beauty treatments | Complements Medicskin with medical-aesthetic and lifestyle beauty services | Aesthetic clients wanting lower-intensity treatments | In-centre | [AR26] |
| facematter professional skincare product line | Cosmeceutical line developed by a team with more than 20 years of cosmeceutical experience; formulations for diverse skin concerns. Individual SKUs and pricing are not disclosed in filings. | Existing clients and online consumers | Own e-shop (facematter.com) and a third-party shopping platform (platform not named) | [AR26][WEB] |
Anti-ageing & Preventive Medicine
| Offering | Description | Target customer | Source |
|---|---|---|---|
| Personalised wellness plans | Comprehensive anti-ageing and preventive care plans | Health-conscious adults | [WEB] |
| Genetic testing | Genetic testing to inform preventive plans | Same | [WEB] |
| Anti-ageing medicine and supplements | Anti-ageing medicines and supplements | Same | [WEB] |
| Health-management / body-check services | Comprehensive body-check service (website imagery); operated via the Rightway Honour sub-group ("Hong Kong Precision and Preventive Medical Centre" entities) | Same | [WEB][AR26] |
Product refresh cadence. The group states it continuously performs market research on the latest products, skills, devices and technology. It regards new services and products as a key growth driver [WEB][AR26]. The FY2026 device refresh is evidenced by HK$1.75m of PP&E additions, of which HK$1.69m was medical equipment. This included a trade-in arrangement in which HK$619k of the purchase price was offset by disposal of existing equipment [AR26 notes 16, 37].
Financial Narrative
All figures are in HK$ thousands unless stated, from [AR26] including its five-year financial summary, except where noted. FY2022–FY2024 cost and cash-flow details come from aggregators [ETNET][MOO][STX] and are flagged.
Income statement
Notes:
-
FY2022–FY2024 staff costs come from [MOO]; directors' emoluments FY2022–FY2024 and D&A FY2022–FY2024 come from [ETNET]. Net finance cost comes from [ETNET] and reconciles to [AR26] for FY2025–FY2026 (finance costs less bank and lease-deposit interest income).
-
EBITDA = PBT + net finance cost + D&A. Under HKFRS 16 this excludes rent, because right-of-use depreciation is added back. It therefore overstates cash earnings; see EBITDA after leases in 6.4.
-
EPS for FY2023 and FY2022 is derived as attributable profit divided by 396,736k shares. FY2024 basic loss per share of HK0.77 cents is corroborated by press coverage [MOO].
-
A special dividend of HK2.5 cents was declared with the FY2021 results [STX][MOO].
Source conflict: FY2024 revenue is HK$49,135k per [AR26]/[ETNET] but HK$49,885k per [STX]/[TR]. The primary filing figure is used.
Revenue CAGR. FY2022–FY2026 (4-year): -0.7%. FY2016–FY2026 (10-year, aggregator series [STX], from about HK$60.1m): about -2.2%. Revenue has oscillated in a HK$41.7–49.9m band since FY2020 [STX][AR26].
FY2026 cost structure
Profit bridge, FY2025 to FY2026. Attributable result moved from HK$-3.38m to HK$+0.94m, a swing of about HK$4.3m:
Note that about HK$0.6m of FY2026 other income (PP&E disposal gain) is non-recurring. Excluding it, the underlying FY2026 pre-tax profit was about HK$0.3m.
Balance sheet
FY2024 cash and lease liabilities come from the opening balances in [AR26] cash flow statement and note 37. The FY2024 bank borrowing of nil comes from [AR26] note 37 (opening balance at 1 April 2024).
Commentary. Equity attributable to owners has eroded from HK$17.4m (FY2022) to HK$5.2m (FY2026). Three causes stand out:
-
cumulative losses of about HK$10.0m over FY2023–FY2025;
-
the October 2024 buy-out of the 49% minority in Rightway Honour, which transferred HK$3.374m of the subsidiary's net liabilities to owners' equity;
-
no capital raising.
The FY2025 jump in total assets to HK$57.4m reflects the HK$9.0m loan proceeds held as cash and the HK$15.0m right-of-use remeasurement on lease renewals. The balance sheet's defining feature is the HK$23.2m contract liability, a non-cash obligation to deliver future treatments. It creates the reported net current liability position (HK$-5.9m) even though unpledged cash and deposits of HK$16.7m exceed bank debt. The pledged deposits of HK$12.7m (HK$10.3m for merchant-acquiring services, HK$2.4m for the bank facility) are economically restricted [AR26 note 21].
Cash flow
Notes:
-
FY2022–FY2024 OCF comes from [STX], an aggregator. [STX] shows FY2026 OCF of HK$5,810k against HK$5,513k in [AR26], so the FY2022–FY2024 aggregator values should be treated as indicative.
-
FY2022 dividends paid are derived as HK$0.025 × 396.736m shares for the July 2021 special dividend [STX].
-
In [AR26], lease interest is presented within "interest paid" in financing activities. The lease-interest figure in this table comes from note 37.
-
FCF after leases = OCF − capex − lease principal − lease interest.
Commentary. Reported free cash flow looks healthy, but it is flattered by HKFRS 16. Once lease payments are deducted (HK$5.8m in FY2026, HK$7.6m in FY2025), the business generated negative cash in FY2026 (about HK$-1.5m). FY2025 benefited from a HK$4.4m inflow of customer prepayments. In FY2026 that reversed into a HK$2.1m outflow as package redemptions exceeded new sales.
Unpledged cash and deposits fell modestly from HK$17.3m to HK$16.7m. Group cash management also shifted: HK$5.2m was placed in six-month deposits, and HK$1.16m was used to buy a US$-denominated life insurance policy on an executive director, now pledged to the bank facility [AR26 notes 17, 21].
Ratios
Notes:
-
The ROE series reconciles to [WS], which shows a maximum annual ROE of 22.50% and a minimum of -80.50%.
-
The current ratio series comes from [VI] and reconciles to [AR26] for FY2025 and FY2026.
-
The FY2025 bank D/E of 2.15x reconciles to [SWS] (214.5%).
-
All other ratios are derived from [AR26].
Trend, inflection and driver commentary
-
Revenue: range-bound, now volatile in alternate years. Revenue swung +17.8%, -7.3%, +7.9%, -8.2% and +6.1% over FY2022–FY2026. Management links the swings to the macro and consumption environment [AR26]: post-COVID reopening, outbound travel and northbound consumption by Hong Kong residents, weak non-residential property, and cautious consumers. Peers show the same pattern. Perfect Medical's revenue fell 14.7% in FY2026 [PMH26], and EC Healthcare's fell 8.9% [ECH26]. Medicskin's +6.1% therefore outperformed both larger peers in FY2026, albeit from a small base.
-
Margin inflection in FY2026 was cost-led. The swing to profit was driven by lower rent (HK$1.9m) and lower staff costs (HK$1.1m) at least as much as by revenue (HK$2.8m) [AR26]. The rent saving is locked in until about February 2028 for the Central centre. The renewed Central rent from February 2028 is HK$295,200 per month (about HK$3.54m a year) [DT1006]. The current rent per centre is not separately disclosed, so the step-change cannot be computed.
-
Founder cost burden. Dr. Kong's total remuneration was HK$6.08m in FY2026 (HK$6.78m in FY2025), equal to 12.7% of revenue. It exceeds the group's profit for the year by about 6.5 times. Part of this reflects his clinical role as a practising doctor in the group [AR26 note 9]. Even so, it is the single largest swing factor in reported profitability.
-
Balance-sheet fragility. Group equity of HK$5.2m and net current liabilities of HK$5.9m leave little buffer. The going-concern basis rests on four supports: FY2026 operating cash inflow, a bank loan scheduled for monthly repayment to 2034 (despite an on-demand clause), no bank demand received, and HK$18.0m of undrawn facilities [AR26 note 3].
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Place / date of incorporation | Ownership | Principal activity |
|---|---|---|---|
Multiple Profit Enterprise Limited | BVI, 1 Feb 2012 | 100% direct | Investment holding |
Medicskin Laboratories Limited (美嫡絲肌科美有限公司) | HK, 12 Jul 2000 | 100% indirect | Medical skincare services (main operating company; tenant of Central centre) |
| — | HK, 19 Sep 2014 | 100% indirect | Skincare product sales and medical skincare services |
互聯美(深圳)貿易有限公司 | Shenzhen, PRC, 19 Aug 2015 | 100% indirect | Skincare product sales (WFOE) |
香港精準及預防醫療中心有限公司 (incorporated 31 Mar 2017) | HK | 100% indirect | Medical consultation services |
Right Success Investment Development Limited | BVI, 18 Sep 2017 | 100% direct | Investment holding |
Rightway Honour Holdings Limited | BVI, 18 Sep 2017 | 100% indirect (51% until 1 Oct 2024) | Investment holding (preventive-medicine sub-group) |
香港精準及預防醫療中心有限公司 (incorporated 9 Oct 2017) | HK | 100% indirect | Skincare and health-management services |
Wealthy Plenty Limited | 19 Sep 2017 | 100% direct | Investment holding |
偉之健抗衰老健康管理(廣州)有限公司 | Guangzhou, PRC, 1 Jun 2018 | 0% (100% at FY2025); disposed FY2026 | Skincare product sales (dormant) |
Revenue by Segment
| Service line (HKD K) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Medical consultation services revenue | — | 1,035 | 954 |
Prescription and dispensing services revenue | — | 8,553 | 7,778 |
Treatment services revenue | — | 35,520 | 39,139 |
Total revenue | 49,135 | 45,108 | 47,871 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansService line share of revenue (%)
| Service line share of revenue (%) | FY2025 | FY2026 |
|---|---|---|
Medical consultation share (%) | 2.3 | 2.0 |
Prescription and dispensing share (%) | 19.0 | 16.2 |
Treatment services share (%) | 78.7 | 81.8 |
Service line YoY growth (%)
| Service line YoY growth (%) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Medical consultation YoY (%) | — | — | -7.8 |
Prescription and dispensing YoY (%) | — | — | -9.1 |
Treatment services YoY (%) | — | — | 10.2 |
Total revenue YoY (%) | 7.9 | -8.2 | 6.1 |
Revenue by Segment and Segment Margins & Growth (%)
| Metric (HKD K) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Segment revenue | 49,135 | 45,108 | 47,871 |
Gross profit (revenue less inventories used) | — | 36,590 | 38,792 |
Gross margin (%) | — | 81.1 | 81.0 |
Operating profit / EBIT (derived: PBT + net finance cost) | -3,273 | -3,782 | 1,065 |
EBIT margin (%) | -6.7 | -8.4 | 2.2 |
Profit before tax | -3,124 | -3,463 | 922 |
Pre-tax margin (%) | -6.4 | -7.7 | 1.9 |
Income Statement and Margin Analysis (%)
| Metric (HKD K) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue | 49,147 | 45,541 | 49,135 | 45,108 | 47,871 |
Revenue growth (%) | 17.8 | -7.3 | 7.9 | -8.2 | 6.1 |
Inventories used (cost of sales) | — | — | — | 8,518 | 9,079 |
Gross profit | — | — | — | 36,590 | 38,792 |
Staff costs (incl. directors) | 20,540 | 23,170 | 24,620 | 23,890 | 22,801 |
Directors' emoluments | 8,820 | 8,826 | 9,951 | 9,587 | 8,700 |
Depreciation & amortisation (RoU + PP&E) | 9,731 | 9,325 | 9,391 | 9,064 | 7,165 |
Net finance cost (income) | -50 | 282 | -149 | -319 | 143 |
EBITDA (derived; HKFRS 16 basis) | 14,102 | 5,904 | 6,118 | 5,282 | 8,230 |
Operating income / EBIT (derived) | 4,371 | -3,421 | -3,273 | -3,782 | 1,065 |
Profit before tax | 4,421 | -3,703 | -3,124 | -3,463 | 922 |
Income tax (expense) / credit | -276 | 113 | 22 | 81 | 14 |
Profit for the year | 4,145 | -3,590 | -3,102 | -3,382 | 936 |
Profit attributable to owners | 3,922 | -3,537 | -3,048 | -3,377 | 936 |
EPS basic and diluted (HK cents) | 0.99 | -0.89 | -0.77 | -0.85 | 0.24 |
Dividend per share declared (HK cents) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin (%)
| Margin (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | — | — | — | 81.1 | 81.0 |
EBITDA margin (%) | 28.7 | 13.0 | 12.5 | 11.7 | 17.2 |
Operating (EBIT) margin (%) | 8.9 | -7.5 | -6.7 | -8.4 | 2.2 |
Pre-tax margin (%) | 9.0 | -8.1 | -6.4 | -7.7 | 1.9 |
Net margin (%) | 8.4 | -7.9 | -6.3 | -7.5 | 2.0 |
Staff cost to revenue (%) | 41.8 | 50.9 | 50.1 | 53.0 | 47.6 |
Directors' emoluments to revenue (%) | 17.9 | 19.4 | 20.3 | 21.3 | 18.2 |
Cost line (HKD K)
| Cost line (HKD K) | FY2025 | FY2026 | Change (%) | Driver per [AR26] |
|---|---|---|---|---|
Inventories used | 8,518 | 9,079 | 6.6 | In line with revenue (19.0% vs 18.9% of revenue) |
Staff costs | 23,890 | 22,801 | -4.6 | Lower directors' emoluments and staff salaries |
RoU depreciation | 7,199 | 5,326 | -26.0 | Lower rents on lease renewals for centres and office |
PP&E depreciation | 1,865 | 1,839 | -1.4 | Stable |
Other expenses | 8,186 | 8,512 | 4.0 | In line with revenue; includes marketing |
Finance costs | 689 | 900 | 30.6 | Lease interest up (HK$631k vs HK$394k) after renewals; bank loan interest HK$259k |
Other income, gains and losses | 1,776 | 1,508 | -15.1 | No repeat of HK$0.5m reinstatement provision write-back; bank interest down HK$0.2m; HK$0.2m fair value loss on insurance policy; partly offset by HK$0.6m PP&E disposal gain |
Driver Details
| Driver | Impact (HKD Mn) |
|---|---|
Revenue growth | +2.8 |
Less higher inventories used | -0.6 |
RoU depreciation savings | +1.9 |
Staff cost savings | +1.1 |
Higher other expenses | -0.3 |
Lower other income | -0.3 |
Higher finance costs | -0.2 |
Tax and NCI | Small |
Balance Sheet
| Metric (HKD K) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets | 56,669 | 46,484 | 40,060 | 57,443 | 51,067 |
Total liabilities | 42,490 | 35,885 | 32,479 | 53,248 | 45,841 |
Total equity | 14,179 | 10,599 | 7,581 | 4,195 | 5,226 |
Equity attributable to owners | 17,431 | 13,912 | 10,950 | 4,195 | 5,226 |
Cash and bank balances incl. 6-month deposits (unpledged) | — | — | 6,927 | 17,344 | 16,734 |
Pledged bank deposits | — | — | — | 13,932 | 12,724 |
Bank borrowings (all classified current) | — | — | 0 | 9,000 | 8,927 |
Lease liabilities, current | — | — | — | 5,147 | 5,092 |
Lease liabilities, non-current | — | — | — | 8,647 | 3,555 |
Total lease liabilities | — | — | 5,757 | 13,794 | 8,647 |
Total debt incl. leases | — | — | 5,757 | 22,794 | 17,574 |
Net debt incl. leases (excl. pledged deposits) | — | — | -1,170 | 5,450 | 840 |
Net debt excl. leases | — | — | -6,927 | -8,344 | -7,807 |
Goodwill and intangibles | — | — | — | 0 | 0 |
Contract liabilities (prepaid packages) | — | — | 20,998 | 25,359 | 23,222 |
Net current assets (liabilities) | — | — | — | -6,168 | -5,907 |
Inventories | — | — | — | 3,632 | 3,619 |
Right-of-use assets | — | — | — | 14,031 | 8,705 |
Cash Flow
| Metric (HKD K) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow | 4,294 | 3,246 | 10,516 | 9,132 | 5,513 |
Capex (PP&E purchases) | — | — | — | 845 | 1,268 |
Free cash flow (OCF less capex) | — | — | — | 8,287 | 4,245 |
Lease principal repaid | — | — | — | 7,245 | 5,147 |
Lease interest paid | — | — | — | 394 | 631 |
FCF after lease payments | — | — | — | 648 | -1,533 |
Dividends paid | 9,918 | 0 | 0 | 0 | 0 |
Share buybacks | — | — | — | 0 | 0 |
Change in contract liabilities (working capital) | — | — | — | 4,361 | -2,137 |
EBITDA after lease payments (EBITDAaL, derived) | — | — | — | -2,357 | 2,452 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE on closing attributable equity (%) | 22.5 | -25.4 | -27.8 | -80.5 | 17.9 |
ROA on closing total assets (%) | 7.3 | -7.7 | -7.7 | -5.9 | 1.8 |
ROIC, EBIT / (equity + total debt − cash) (%) | — | — | -51.1 | -39.2 | 17.6 |
Current ratio (x) | 1.01 | 0.91 | 0.93 | 0.86 | 0.86 |
Debt / equity incl. leases (x) | — | — | 0.76 | 5.43 | 3.36 |
Bank debt / equity (x) | — | — | 0.00 | 2.15 | 1.71 |
Gearing per company definition: interest-bearing debt / total assets (%) | — | — | 14.4 | 39.7 | 34.4 |
Net debt incl. leases / EBITDA (x) | — | — | -0.19 | 1.03 | 0.10 |
EBITDA / finance costs (x) | — | — | — | 7.7 | 9.1 |
EBIT / finance costs (x) | — | — | — | -5.5 | 1.2 |
Asset turnover (x) | 0.87 | 0.98 | 1.23 | 0.79 | 0.94 |
Inventory days | — | — | — | 156 | 146 |
Receivable days | — | — | — | 5 | 3 |
Payable days | — | — | — | 33 | 31 |
Cash conversion cycle, accounting basis (days) | — | — | — | 128 | 118 |
Region revenue (HKD K)
| Region revenue (HKD K) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Hong Kong revenue | 49,147 | 45,541 | 49,135 | 45,108 | 47,871 |
Mainland China revenue | 0 | 0 | 0 | 0 | 0 |
Rest of world revenue | 0 | 0 | 0 | 0 | 0 |
Region growth (%)
| Region growth (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Hong Kong revenue growth (%) | 17.8 | -7.3 | 7.9 | -8.2 | 6.1 |
Service Line Details
| Service line (HKD K) | Hong Kong | Mainland China | Total |
|---|---|---|---|
Medical consultation | 954 | 0 | 954 |
Prescription & dispensing | 7,778 | 0 | 7,778 |
Treatment services | 39,139 | 0 | 39,139 |
Total | 47,871 | 0 | 47,871 |
Share Price History
| Date | Price (HKD) | Implied market cap (HKD Mn) |
|---|---|---|
18 Dec 2014 (IPO) | 0.600 | 238.0 |
about 1 Oct 2025 | about 0.138 (implied) | 54.75 |
about 8 Nov 2025 | about 0.199 (implied) | 78.95 |
3 Apr 2026 | 0.169 | 67.05 |
24 Apr 2026 | 0.143 | 56.7 |
10 Jul 2026 | 0.118 | 46.8 |
22 Jul 2026 (latest verified) | 0.123 | 48.8 |
Share Price & Returns
| Horizon | Performance |
|---|---|
1-year | About -28% (market cap -27.6% year-on-year at 10 Jul 2026); Simply Wall St shows -29% at HK$0.14 |
1-quarter (to 10 Jul 2026) | -21.0% |
Since Jan 2017 | -87.2% |
Since IPO | -79.5% on unadjusted HK$0.60 vs HK$0.123. Stoxray shows -96.5%; the discrepancy (possibly dividend or other adjustment) could not be reconciled. |
52-week range | HK$0.025–0.240 per [SA]. The low appears anomalous and may be a data error. |
Beta | -0.14 (illiquid; not meaningful) |
Valuation Multiples
| Multiple | Medicskin (8307) | EC Healthcare (2138) |
|---|---|---|
Market cap (HKD Mn) | 48.8 | about 474 at HK$0.40 |
P/E (x) | 52.1 | n/m (loss) |
P/B (x) | 9.3 | Not computed |
EV / Sales (x), incl. leases | 1.04 | Not computed |
EV / EBITDA (x), HKFRS 16 incl. leases | 6.0 | n/m (LBITDA HK$-110.1m) |
EV / EBITDAaL (x), ex-leases | 16.7 | — |
P/S (x) | 1.02 | about 0.13 |
Dividend (HK cents per share)
| Dividend (HK cents per share) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Interim and final dividend per share (HK cents) | 0 | 0 | 0 | 0 | 0 |
Debt Maturity Profile
| Maturity bucket | Bank borrowings (scheduled) | Lease liabilities |
|---|---|---|
Within 1 year | 851 | 5,092 |
1–2 years | 1,047 | 3,555 |
2–5 years | 3,320 | 0 |
Over 5 years | 3,709 | 0 |
Total | 8927 | 8647 |
Analyst Conclusions
Management guidance
No quantitative guidance is provided. Management's qualitative outlook for 2026 [AR26]:
-
persistent geopolitical and macro uncertainty;
-
intense competition;
-
encouraging signs of recovery in Hong Kong retail and services;
-
steady medium- to long-term demand growth in medical aesthetics.
Planned actions are continued operational optimisation, refined marketing, and renovation of the medical skincare centre(s).
Consensus growth expectations
There is no consensus because there is no coverage. The analyst base case, derived for FY2027:
Revenue: flat to low single-digit growth. Treatment demand is supportive, but the 16.5% fall in new prepaid package receipts and the 8.4% decline in contract liabilities point to softer recognisable revenue ahead.
Profitability: near break-even. The FY2026 profit included a non-recurring HK$0.6m disposal gain, and renovation-related disruption or costs may weigh.
Bull case
-
Operating leverage on a fixed cost base. Rent savings are locked in until about 2028, and staff costs are already reduced. Each incremental HK$1m of revenue at about 81% gross margin drops largely to profit. A return to the FY2022 revenue level (HK$49.1m) would roughly double FY2026's underlying profit.
-
Regulatory moat strengthening. Hong Kong's push to reserve injectables and high-risk procedures for doctors [CIS][LEGCO] structurally favours Medicskin's physician-led model over non-medical salons.
-
Peer retrenchment opens share. Perfect Medical is closing underperforming Hong Kong outlets, and EC Healthcare is loss-making [PMH26][ECH26]. Medicskin grew 6.1% while both shrank. A renovated Central flagship with tenure to 2030 could capture displaced high-end clients.
Bear case
-
Backlog drawdown masks weakening bookings. FY2026 treatment revenue was helped by recognising HK$19.2m of opening contract liabilities, while new package receipts fell to HK$17.1m. Sustained weakness would hit both revenue and cash. FCF after leases was already negative (about HK$-1.5m).
-
Key-person and governance risk. The 72-year-old founder is Chairman, CEO, controlling shareholder (69.3%) and practising doctor. He takes HK$6.1m in remuneration, about 6.5 times group profit, and personally guarantees the bank facilities. No succession plan is disclosed.
-
Fragile capital base and valuation. Equity is HK$5.2m, net current liabilities are HK$5.9m, and debt including leases is 3.4x equity. The stock trades at 52x earnings and 9.3x book with negligible liquidity and no dividend capacity. Any return to losses would quickly erode equity and could pressure bank covenants or GEM listing standing.
Key catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | What to watch |
|---|---|---|
| Interim results, six months to 30 Sep 2026 | By about mid-Nov 2026 (board meeting notice filed 29 Sep 2026) | Treatment revenue growth; contract-liability trend (new package sales); staff-cost discipline |
| Centre renovation | Timing undisclosed | Capex size, disruption to Central centre revenue, financing |
| Lease renewal for TST / Ocean Centre | Before current leases expire (all lease liabilities run off within 2 years) | Rent level vs current; RoU remeasurement |
| Hong Kong regulatory developments | Ongoing | Medical-device / high-risk procedure legislation; injectable classification implementation |
| Founder succession or board refresh | Any time | INED tenure over 9 years for two directors; any CEO succession signals |
| Capital actions | Any time | Use of buy-back mandate; any placing (equity is thin); dividend resumption unlikely |
| FY2027 annual results | About June 2027 | Sustainability of profit without the one-off disposal gain |
Concluding analyst verdict
Medicskin Holdings is a well-run but structurally constrained boutique: two doctor-led medical aesthetics clinics inside a GEM-listed shell. Its FY2026 turnaround is genuine but modest. Revenue rose 6.1% to HK$47.9 million against double-digit declines at larger peers, and the group swung from a HK$3.4 million loss to a HK$0.9 million profit. The quality of that profit, however, deserves scrutiny.
Roughly two-thirds of the improvement came from cost actions, mainly lower rents on lease renewals and reduced staff and director pay, rather than from demand. About HK$0.6 million of the result was a non-recurring equipment disposal gain. The underlying operating profit is therefore close to break-even.
The prepaid-package model is both the group's financial strength and its blind spot. Customer prepayments of HK$23.2 million fund operations and give revenue visibility. But FY2026 receipts from new packages fell 16.5%, and contract liabilities shrank. That suggests FY2026 treatment growth partly consumed the backlog rather than rebuilding it. After lease payments, the business consumed cash.
Governance and capital structure are the binding constraints:
-
The founder controls 69% of the equity and combines the Chair, CEO and lead-clinician roles.
-
He receives remuneration several times group profit and personally guarantees the bank facilities.
-
Equity is only HK$5.2 million, and net current liabilities persist.
The early extension of the Central flagship lease to 2030 and the planned renovation signal commitment to the core franchise. They also add fixed-cost and capex risk.
At HK$0.123, the market values the company at about HK$49 million: 52x trailing earnings, 9.3x book and about 17x rent-adjusted EBITDA. For a sub-scale, illiquid, controlled micro-cap with no dividend capacity and no stated succession plan, this valuation already discounts a sustained recovery.
The analytical stance is cautious. The business is viable and clinically credible, but evidence of rebuilding prepaid bookings is needed before the FY2026 inflection can be treated as durable. The interim results due around November 2026 are the next decisive data point.
Appendix A: Data limitations and conflicts
-
FY2024 revenue: HK$49,135k per [AR26]/[ETNET] vs HK$49,885k per [STX]/[TR]. The primary filing figure is used.
-
FY2026 operating cash flow: HK$5,513k per [AR26] vs HK$5,810k per [STX]. The primary figure is used; FY2022–FY2024 OCF comes only from [STX] and is indicative.
-
Distributable reserves: the AR26 directors' report says none at company level, while the financial statements show positive reserves at company (HK$1,081k) and group (HK$1,259k) level.
-
Workforce gender ratio: the AR26 CG report text (21:79 female:male) conflicts with the ESG chart and narrative (about 79% female).
-
Since-IPO share performance: -79.5% unadjusted vs -96.5% per [STX]; not reconciled.
-
52-week low: HK$0.025 per [SA] appears anomalous.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Appointed / tenure | Age | Education / credentials | Prior roles / other |
|---|---|---|---|---|---|
Dr. Kong Kwok Leung (江覺亮) | Chairman, CEO, Executive Director; founder and practising doctor; Chair of Nomination Committee; member of Remuneration Committee | Founder (2000); listed-co director since 2014 | 72 | MBBS (HKU, 1978); DCH (RCP London, 1985); Dip Dermatology (Univ. of London, 1995); PG Dip Practical Dermatology (Cardiff, 2007) | Over 40 years in private practice; over 30 years in medical aesthetics. Domestic partner of Ms. Tsui Kan; uncle of Ms. Kong Chung Wai. |
Ms. Tsui Kan (徐勤) | Executive Director; Vice President | Joined Jan 2016 | 42 | LLB, Zhejiang University (2004) | Oversees product development and marketing strategy; domestic partner of Dr. Kong |
Ms. Kong Chung Wai (江聰慧) | Executive Director; Legal & Compliance Officer; Compliance Officer; authorised representative; Nomination Committee member | Joined 2001 | 48 | BBA Accounting (HKUST, 2000); LLB (Univ. of London, 2010); FCCA since 2010 | Over 25 years in accounting, audit and compliance; niece of Dr. Kong |
Ms. Sin Chui Pik Christine (冼翠碧) | Executive Director; CFO; Company Secretary; Remuneration Committee member | Joined Mar 2014; Company Secretary since 23 Jun 2014 | 47 | BBA Accounting (HKBU, 2001); FCPA; FCCA | Deloitte Touche Tohmatsu 2001–2004 and 2005–2014 (Manager). INED of Zhongxing Group Holdings (55.HK) since Sep 2023. |
Mr. Chan Cheong Tat (陳昌達) | INED; Chair of Audit Committee | 3 Dec 2014 (over 11 years) | 76 | MFin Mgmt (Central Queensland Univ., 1995); FCPA, FCCA, CPA Australia; Chartered Secretary | Hong Kong Inland Revenue Department for over 32 years (retired 2005 as Assistant Commissioner). Sole director of a tax advisory firm since 2006. INED of 8512, 8537, 1941 and 3393; formerly INED of 1283 (Sep 2019–Mar 2026). |
Mr. Leung Siu Cheung (梁兆祥) | INED; Chair of Remuneration Committee | 3 Dec 2014 (over 11 years) | 74 | Law Society Finals (1982); LLM Chinese & Comparative Law (CityU, 2004) | Practising solicitor since Oct 1983; partner of a Hong Kong law firm since 1986; also qualified in England & Wales and in ACT and NSW, Australia |
Mr. Lui Sze On (呂思安) | INED | 6 Sep 2023 | 53 | Not specified | Over 20 years of service-industry management; major hotel groups 1989–2018; office administration centre manager, China Resources (Holdings) 2021–2023 |
| — | Head of Business & Product Development; Medicskin Centre Manager (senior management, non-board) | Joined Jan 2013 | 46 | BSc Nutritional Sciences (UBC, 2002); Advanced Diploma in International Administrative Management (2006) | Product manager at a cosmetics company 2007–2012; business development roles 2004–2007 |
Directors' Remuneration
| Director (HKD K) | Fees | Salary & allowances | Performance bonus | Service fees | Pension | Total FY2026 | Total FY2025 |
|---|---|---|---|---|---|---|---|
Dr. Kong Kwok Leung | 60 | 4,320 | 1,698 | 0 | 0 | 6,078 | 6,776 |
Ms. Tsui Kan | 60 | 485 | 20 | 0 | 18 | 583 | 764 |
Ms. Kong Chung Wai | 60 | 0 | 0 | 411 | 0 | 471 | 455 |
Ms. Sin Chui Pik Christine | 60 | 916 | 34 | 0 | 18 | 1,028 | 1,052 |
Mr. Chan Cheong Tat | 180 | 0 | 0 | 0 | 0 | 180 | 180 |
Mr. Leung Siu Cheung | 180 | 0 | 0 | 0 | 0 | 180 | 180 |
Mr. Lui Sze On | 180 | 0 | 0 | 0 | 0 | 180 | 180 |
Total | 780 | 5,721 | 1,752 | 411 | 36 | 8700 | 9587 |
Governance Overview
| Attribute | Status |
|---|---|
Board size | 7 (4 executive, 3 INEDs) |
Independence | 43% independent (minimum 3 INEDs per GEM Rule 5.05) |
Gender diversity | 3 of 7 directors female (43%); no numerical target set |
Chair / CEO separation | Not separated. Dr. Kong holds both roles, a disclosed deviation from CG Code C.2.1 |
Family relationships on board | Chairman's domestic partner (Tsui) and niece (Kong CW) are executive directors |
INED tenure | Two of three INEDs have served over 9 years; separate shareholder resolutions approved at the 2024 AGM |
Committees | Audit (3 INEDs; chair Chan); Remuneration (chair Leung; 2 EDs + 3 INEDs); Nomination (chair Dr. Kong; 2 EDs + 3 INEDs). Committee terms of reference re-published 22 Jun 2026. |
Meetings FY2026 | Board 4 (100% attendance); Audit 4; Remuneration 1; Nomination 1; Chairman–INED meetings 2 |
AGM attendance | Ms. Tsui and Ms. Kong CW did not attend the 15 Sep 2025 AGM |
Corporate governance committee | None; the board performs CG functions |
Whistleblowing | Policy in place; reports escalate to the Audit Committee chair |
D&O insurance | In place |
Major Shareholders
| Holder | Shares | % of issued | Type |
|---|---|---|---|
Topline Worldwide Limited (wholly owned by Dr. Kong Kwok Leung) | 274,865,400 | 69.28 | Controlling shareholder (insider) |
Public float (no other holder above 5% disclosed) | 121,870,600 | 30.72 | Public |
Competitive Landscape
Key Competitors
| Competitor | Type | Latest revenue | Relative positioning vs Medicskin |
|---|---|---|---|
Perfect Medical Health Management (1830.HK) | Listed multi-brand medical aesthetics chain (HK, PRC, Macau, Australia, Singapore) | FY2026 HK$962.3m; profit HK$178.3m; payout of 100% or more for 11 straight years; rightsizing HK outlets; Oracle (Korea) cooperation | About 20x Medicskin's revenue; scale purchasing, marketing reach, zero-borrowing balance sheet |
EC Healthcare (2138.HK) | Listed non-hospital healthcare platform (medical, aesthetic medical, beauty and wellness, veterinary) | FY2026 HK$3,770.2m total; aesthetic medical and beauty & wellness HK$1,322.9m; net loss HK$412.9m | Aesthetic segment about 28x Medicskin's revenue; one-stop ecosystem; financially strained |
Modern Beauty Salon Holdings (919.HK) | Listed beauty-salon and wellness chain | — | Lower-acuity beauty services; price competitor for non-medical treatments |
Natural Beauty Bio-Technology (157.HK) | Listed beauty-services and skincare group | — | Skincare and beauty-services overlap with facematter |
Medilase (private) | Hong Kong laser-aesthetics clinic chain | — | Direct competitor in laser and energy-based treatments |
Independent dermatologist and doctor-run aesthetic clinics (Central, TST) | Fragmented private practices | — | Same doctor-led proposition; compete for doctors and clients |
Non-medical beauty salons | Fragmented | — | Cheaper, less regulated alternatives |
Shenzhen medical-aesthetic clinics (northbound consumption) | Cross-border substitute | — | Lower prices; drain on Hong Kong local demand |
Korean and Japanese aesthetic clinics (outbound medical tourism) | Cross-border substitute | — | Outbound travel diverts spending |
“—” = not publicly disclosed.
Peer Comparison FY2026
| Metric | Medicskin (8307) | Perfect Medical (1830) | EC Healthcare (2138) |
|---|---|---|---|
Revenue (HKD Mn) | 47.9 | 962.3 | 3,770.2 |
Revenue growth (%) | 6.1 | -14.7 | -8.9 |
Profit for the year (HKD Mn) | 0.9 | 178.3 | -412.9 |
Net margin (%) | 2.0 | 18.5 | -11.0 |
Aesthetic / beauty revenue (HKD Mn) | 47.9 | Not separated in data reviewed | 1,322.9 |
Contract liabilities / deferred revenue (HKD Mn) | 23.2 | 196.4 (2.7 + 193.7) | 539.1 |
Dividend | — | HK14.6 cents (payout 102.8%) | — |
Recent Developments
Company-specific events are drawn from the announcements register on [WEB] and the content of [AR26], [PPA26] and [DT1006]. Industry and peer events are included where they directly affect Medicskin's operating context.
The register shows no first-quarterly results for the quarter to 30 June 2026. The annual report refers to quarterly reports only "if any", consistent with GEM no longer requiring mandatory quarterly reporting [WEB][AR26].



